Abstract:Abstract Background Without an effective strategy for targeted therapy, glioblastoma multiforme (GBM) is still incurable, with a median survival of only 15 months. Both chronic inflammation and epigenetic reprogramming are hallmarks of cancer. However, the mechanisms and consequences of their cooperation in GBM remain unknown. Methods Western blotting was carried out to detect levels of various histone modifications affected by NF-κB signalling. Then, RNA-seq was used to screen genes encoding methyltransferases and demethylases of histone. Dual-luciferase reporter gene and ChIP assays were performed to determine whether NF-κB activates the transcription of EZH2. Subsequently, ChIP-seq and RT-qPCR were performed to explore the variety of H3K27me3 distribution. Expression levels of p65 and EZH2 in glioma samples were evaluated by IHC, and tumorigenicity assays (in vitro and in vivo) were performed to demonstrate the effects of combining NF-κBi and EZH2i on GBM progression. Results We discovered that chronic inflammation governs H3K27me3 reprogramming in GBM through the canonical NF-κB pathway to target EZH2. Being a crucial mediator of chronic inflammation, the canonical NF-κB signalling specifically directs the expression and redistribution of H3K27me3 but not H3K4me3, H3K9me3 and H3K36me3. Then, we identified EZH2 as a key methyltransferase to control inflammation-triggered epigenetic reprogramming in gliomagenesis. Mechanistically, NF-κB selectively drives the expression of EZH2 by activating its transcription, consequently resulting in a global change of H3K27me3 expression and distribution. Furthermore, we find that co-activation of NF-κB and EZH2 confers the poorest clinical outcome, and that the risk for GBM can be accurately molecularly stratified by NF-κB and EZH2. It is notable that NF-κB can potentially cooperate with EZH2 in more than one way, and most importantly, we demonstrated a synthetic lethality of cancer cells induced by combinatory inhibition of NF-κB and EZH2, which both are frequently over-activated in GBM. Conclusions We uncover a functional cooperation between chronic inflammation and epigenetic reprogramming in GBM. Thus, combined targeting of NF-κB and EZH2 by inhibitors can be a potent strategy for the effective treatment of this fatal disease.

Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme

DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis

Inhibition of Notch Signaling Blocks Growth of Glioblastoma Cell Lines and Tumor Neurospheres.

TCF3 Induces DNMT1 Expression to Regulate Wnt Signaling Pathway in Glioma

Synthetic Lethality Through GSK3 Inhibition in Glioma Stem Cells Via the WNT-WWC1-YAP Axis

CDK7 Inhibition is a Novel Therapeutic Strategy Against GBM Both in Vitro and in Vivo.

Inhibition of FAM83D Displays Antitumor Effects in Glioblastoma Via Down‐regulation of the AKT/Wnt/β‐catenin Pathway

Upregulated FKBP1A Suppresses Glioblastoma Cell Growth Via Apoptosis Pathway

Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth

Epco-27. Chromatin Remodeling Reprograms The Transcription Network In Glioblastoma

Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells

Targeting Cooperation of Chronic Inflammation with Epigenetic Reprogramming Triggers a Synthetic Lethality in Glioblastoma Multiforme

EPIG-02DYNAMIC EPIGENETIC MODULATION OF GLIOBLASTOMA TUMORIGENICITY BY INHIBITION OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1)

Histone Demethylase KDM4B Accelerates the Progression of Glioblastoma Via the Epigenetic Regulation of MYC Stability

CBIO-10. TARGETING HISTONE H4 Lys 20 MONOMETHYLATION IN THE TREATMENT OF GLIOBLASTOMA

TARGETING TRANSCRIPTIONAL ADDICTION FOR GBM THERAPY THROUGH CDK7 INHIBITION

EXTH-19. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA

DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.

DIPG-14. INTEGRATED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) NEXT-GENERATION SEQUENCING REVEALS EPIGENETIC DYSREGULATION OF GENE EXPRESSION AND BROMODOMAIN INHIBITION AS A NOVEL THERAPEUTIC TARGET

Csig-26. Targeting Epigenetic Dysregulation And Adaptive Resistance Mechanisms In Dipg/Dmg

Knockdown of DEPDC1B inhibits the development of glioblastoma